Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : King Pharmaceuticals, Inc. (Nasdaq:KG)(Was KING) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (21)	5/27/1999 3:44:00 PM
From: wpckr	Respond to of 61

I do not see an immediate upside and what you say is true. I am a lurker here and have never bought in to this stock.

To: Harold Engstrom who wrote (21)	5/27/1999 6:46:00 PM
From: Quahog	Read Replies (1) \| Respond to of 61

A friend of mine, who works for King, describes the upside as this: King, and Monarch, are constantly looking for established products (drugs) that are profitable but not superstars, to purchase. King then remarkets the product in the hope of boosting sales. The upside then, according to this fellow, is that there is very little risk and a lot of potential. King may not become a superstar overnight, but it should continue a slow and steady rise in that direction. Plus, for a pharmaceutical company, the price is right. Whether this is simply the company line, or the truth, I do not know. It sounds reasonable to me. Quahog